Novo Nordisk A/S (NYSE: NVO) is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight loss drug, Wegovy.
Addressing the ambitious objective, CEO Lars Jørgensen highlighted the willingness of Novo Nordisk to exhibit flexibility in pricing strategies, intending to facilitate the upfront adoption of medications, allowing for subsequent payments over an extended duration, the Financial Times noted.
Despite facing competition from Eli Lilly And Co's (NYSE: LLY) Zepbound, which plans to introduce a weight-loss drug priced 20% lower than Wegovy, Novo Nordisk remains firm on retaining Full story available on Benzinga.com